Table 2.

Characteristics related to T2D in participants with non-MASLD and MASLD (subdivided into isolated steatosis and advanced fibrosis) (n = 308). For categorical variables, data are presented as the number of participants (percentage). For continuous variables, data are presented as median (IQR). P-values were calculated to compare differences between groups. For categorical variables, comparisons were made using Fisher’s exact test. For continuous variables, the Kruskal–Wallis test was used. Bold values indicate statistically significant differences

	Non-MASLD	Isolated steatosis	Advanced fibrosis	p-value
N	127	161	20
Duration (years)	7 (IQR 3–13)	7 (IQR 3–12)	5 (IQR 2–11)	n.s.
HbA1c (mmol/mol)	48 (IQR 43–54)	50 (IQR 46–58)	51 (IQR 44–59)	0.021
Current T2D treatment
Pharmacological treatment	110 (87%)	133 (83%)	18 (90%)	n.s.
Metformin	93 (73%)	126 (79%)	16 (80%)	n.s.
Pioglitazon	1 (1%)	0 (0%)	0 (0%)	n.s.
DPP4 inhibitors	3 (3%)	2 (1%)	0 (0%)	n.s.
Insulin	23 (19%)	37 (24%)	5 (25%)	n.s.
Sulfonylurea	12 (10%)	14 (9%)	1 (5%)	n.s.
GLP-1 RAs	5 (4%)	13 (8%)	1 (5%)	n.s.
SGLT2 inhibitors	35 (29%)	41 (26%)	10 (50%)	n.s.
Microvascular complications
Neuropathy	29 (23%)	31 (20%)	4 (20%)	n.s.
Retinopathy	27 (22%)	27 (17%)	6 (32%)	n.s.
Albuminuria	19 (15%)	30 (20%)	4 (20%)	n.s.
MDRD GFR < 60	8 (6%)	6 (4%)	2 (10%)	n.s.
Albuminuria or MDRD GFR < 60	22 (17%)	31 (20%)	6 (30%)	n.s.
Foot ulcers	4 (3%)	9 (6%)	0 (0%)	n.s.
Any microvascular complication	62 (49%)	76 (48%)	13 (65%)	n.s.

Abbreviations: DDP4 dipeptidyl peptidase 4, GFR glomerular filtration rate, GLP-1RAs glucagon-like peptide-1 receptor agonists, HbA1c hemoglobin A1c, MASLD metabolic dysfunction-associated steatotic liver disease, MDRD modification of diet in renal disease, n.s. not significant, SGLT2 sodium-glucose cotransporter-2, T2D type 2 diabetes